19 March 2026

Vulcan Two Group plc

(the "Company")

Completion of Acquisitions,

Completion of Placing and

Re-admission to trading

Vulcan Two Group plc, the company aiming to create the UK's leading regulated ePharmacy through buy-and-build, is pleased to announce that, further to the announcement on 26 February 2026 (the "Launch Announcement"), it has now completed the acquisition of CloudRx, Hyperdrug and Webmed (the "Targets"). The Company has also completed an institutional Placing for £40 million, the detail of which was included in the Launch Announcement.

The acquisition of the Targets, individually and collectively, constituted a Reverse Takeover pursuant to Rule 14 of the AIM Rules for Companies. Accordingly, having received shareholder approval at a General Meeting on 17 March 2026, the Company's existing Ordinary Shares were re-admitted to trading on AIM at 8.00 a.m. this morning, alongside the new Ordinary Shares issued pursuant to the Placing and the Acquisitions ("Re-admission").

Directorate Changes

As set out in the Launch Announcement, Keith Butcher has been appointed to the Company's Board of Directors with effect from Re-admission.

Total Voting Rights

Following Re-admission, the Company's total issued share capital now consists of 27,275,000 Ordinary Shares. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Other than where defined, capitalised terms used in this announcement have the meanings given to them in the Launch Announcement.

For further information please contact: